Berlin – Leaps by Bayer, the impact investment arm of Bayer AG, has led a USD 90 million Series B investment in Berlin-based digital health company Ada Health GmbH (“Ada”). Additional investors joined the round, including Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures.

The investment will help advance Ada’s popular health assessment technology, enabling the digital health pioneer to accelerate its path towards becoming the world's leading personalized operating system for health, as well as to further grow the company’s leading position in the United States. In addition to today’s announcement, Bayer and Ada Health are in discussions about entering into a longer-term strategic partnership to support the company’s healthcare businesses.

Ada Health has developed a powerful AI-based health assessment and care navigation platform that helps users to understand their symptoms, to identify and differentiate conditions with a high degree of medical accuracy, and to navigate safely to the right care, at the right time. Ada’s consumer app has become the world’s most popular and highest-rated symptom assessment app, with over 23 million assessments completed since its global launch.

Prof. Dr. Hans-Eric Rasmussen-Bonne has been associated with Ada Health since 2015 and, together with the venture capital team at the Berlin office, advised the shareholder BBPM GmbH and other shareholders in the financing round that has now been completed.

Weitnauer Team

Prof. Dr. Hans-Eric Rasmussen-Bonne, LL.M. (Handels- und Gesellschaftsrecht/Berlin)

Andreas Michael, LL.M. (Handels- und Gesellschaftsrecht/Berlin)